Birdwatch Note
2024-10-31 07:16:59 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
日本において、ガーダシルは4価ワクチン(4種類のHPVの感染を防ぐ)で、シルガード9は9価ワクチン(9種類のHPVの感染を防ぐ)で違うものですので、誤解を招く投稿です。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/hpv_9-valentHPVvaccine.html 両者のより詳細な違いは下記をご参照下さい。 https://www.msdconnect.jp/products/gardasil-silgard9/ 両方ともMSDから販売されています。 https://www.msdconnect.jp/products/gardasil-silgard9/ 欧州等ではMSDの9価ワクチンはGardasil 9である事は正しい情報です。 https://www.ema.europa.eu/en/medicines/human/referrals/human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard 4価も欧州で発売された時は、GardasilとSilgardの2つのブランド名がありました。 https://www.medscape.com/viewarticle/545374?form=fpf しかし、Silgardとしての申請は2019年に取り下げられておりGardasilのみが現在有効です。 https://www.ema.europa.eu/en/documents/public-statement/public-statement-silgard-withdrawal-marketing-authorisation-european-union_en.pdf https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil https://www.ema.europa.eu/en/medicines/human/EPAR/silgard
Written by 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1851842687730880885
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1851886065470373898
- noteId - 1851886065470373898
- participantId -
- noteAuthorParticipantId - 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE Participant Details
- createdAtMillis - 1730359019044
- tweetId - 1851842687730880885
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 日本において、ガーダシルは4価ワクチン(4種類のHPVの感染を防ぐ)で、シルガード9は9価ワクチン(9種類のHPVの感染を防ぐ)で違うものですので、誤解を招く投稿です。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/hpv_9-valentHPVvaccine.html 両者のより詳細な違いは下記をご参照下さい。 https://www.msdconnect.jp/products/gardasil-silgard9/ 両方ともMSDから販売されています。 https://www.msdconnect.jp/products/gardasil-silgard9/ 欧州等ではMSDの9価ワクチンはGardasil 9である事は正しい情報です。 https://www.ema.europa.eu/en/medicines/human/referrals/human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard 4価も欧州で発売された時は、GardasilとSilgardの2つのブランド名がありました。 https://www.medscape.com/viewarticle/545374?form=fpf しかし、Silgardとしての申請は2019年に取り下げられておりGardasilのみが現在有効です。 https://www.ema.europa.eu/en/documents/public-statement/public-statement-silgard-withdrawal-marketing-authorisation-european-union_en.pdf https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil https://www.ema.europa.eu/en/medicines/human/EPAR/silgard
Note Ratings
rated at | rated by | |
2024-10-31 05:48:55 -0500 | Rating Details | |
2024-10-31 05:19:39 -0500 | Rating Details | |
2024-10-31 04:59:36 -0500 | Rating Details | |
2024-10-31 03:56:37 -0500 | Rating Details | |
2024-10-31 03:49:32 -0500 | Rating Details | |
2024-10-31 03:25:28 -0500 | Rating Details | |
2024-10-31 02:24:28 -0500 | Rating Details | |
2024-10-31 18:36:34 -0500 | Rating Details | |
2024-10-31 09:52:07 -0500 | Rating Details | |
2024-10-31 05:10:46 -0500 | Rating Details | |
2024-10-31 05:05:24 -0500 | Rating Details | |
2024-10-31 04:25:05 -0500 | Rating Details | |
2024-10-31 04:10:00 -0500 | Rating Details | |
2024-10-31 03:44:40 -0500 | Rating Details | |
2024-10-31 03:44:13 -0500 | Rating Details | |
2024-10-31 03:40:52 -0500 | Rating Details | |
2024-10-31 03:31:51 -0500 | Rating Details | |
2024-10-31 17:25:02 -0500 | Rating Details | |
2024-10-31 09:29:30 -0500 | Rating Details | |
2024-10-31 08:30:45 -0500 | Rating Details | |
2024-10-31 08:16:45 -0500 | Rating Details | |
2024-10-31 07:02:27 -0500 | Rating Details | |
2024-10-31 05:14:34 -0500 | Rating Details | |
2024-10-31 04:40:44 -0500 | Rating Details | |
2024-10-31 04:20:46 -0500 | Rating Details | |
2024-10-31 04:20:45 -0500 | Rating Details | |
2024-10-31 04:02:03 -0500 | Rating Details | |
2024-10-31 03:55:09 -0500 | Rating Details | |
2024-10-31 03:53:11 -0500 | Rating Details | |
2024-10-31 02:39:36 -0500 | Rating Details | |
2024-10-31 02:25:13 -0500 | Rating Details | |
2024-11-01 01:55:01 -0500 | Rating Details | |
2024-11-01 01:17:21 -0500 | Rating Details | |
2024-10-31 21:20:37 -0500 | Rating Details | |
2024-10-31 19:01:04 -0500 | Rating Details | |
2024-10-31 08:57:33 -0500 | Rating Details | |
2024-10-31 07:52:21 -0500 | Rating Details | |
2024-10-31 07:07:55 -0500 | Rating Details | |
2024-10-31 06:51:46 -0500 | Rating Details | |
2024-10-31 06:38:53 -0500 | Rating Details | |
2024-10-31 03:44:15 -0500 | Rating Details | |
2024-10-31 03:39:24 -0500 | Rating Details | |
2024-10-31 03:37:16 -0500 | Rating Details | |
2024-10-31 03:36:20 -0500 | Rating Details | |
2024-10-31 03:10:23 -0500 | Rating Details | |
2024-10-31 20:44:50 -0500 | Rating Details | |
2024-10-31 10:18:00 -0500 | Rating Details | |
2024-10-31 06:54:21 -0500 | Rating Details | |
2024-10-31 06:45:25 -0500 | Rating Details | |
2024-10-31 06:34:25 -0500 | Rating Details | |
2024-10-31 04:52:23 -0500 | Rating Details | |
2024-10-31 04:48:31 -0500 | Rating Details | |
2024-10-31 04:42:14 -0500 | Rating Details | |
2024-10-31 04:10:17 -0500 | Rating Details | |
2024-10-31 03:44:38 -0500 | Rating Details | |
2024-10-31 03:43:32 -0500 | Rating Details | |
2024-10-31 03:25:46 -0500 | Rating Details | |
2024-10-31 03:14:54 -0500 | Rating Details | |
2024-10-31 02:38:37 -0500 | Rating Details |